Currently Enrolling Trials
Trovan (trovafloxacin), a broad-spectrum antibiotic, has been approved for the treatment of 14 bacterial infections.
In June of 1999 the Food and Drug Administration issued a public health advisory to physicians concerning the risks of liver toxicity associated with the use of Trovan (trovafloxacin, an oral antibiotic) and Trovan-IV (alatrofloxacin, the intravenous formulation of the drug). This action followed postmarketing reports of rare but severe liver injuries leading to transplants and deaths. The drug was subsequently discontinued.
Mechanism of Action
Trovan is a member of the quinolone class of antibiotics.